<DOC>
	<DOCNO>NCT01992367</DOCNO>
	<brief_summary>This single-centre , placebo-controlled , randomised , double-blind study evaluate safety tolerability single ascending dos ( SAD ) multiple ascend dos ( MAD ) ASLAN003 healthy subject</brief_summary>
	<brief_title>Phase 1 , Randomised Double Blinded Placebo Controlled Study ASLAN003</brief_title>
	<detailed_description>This single-centre , placebo-controlled , randomised , double-blind study involve SAD MAD ASLAN003 healthy subject . The study divide two part : - Part A : SAD cohort 1 cohort ass food effect ASLAN003 PK . - Part B : MAD cohorts one cohort healthy elderly subject . There sentinel pair subject SAD Cohorts 1 , 2 3 dose first dose give rest subject respective cohort . In addition , 8 subject receive ASLAN003 fed fast condition</detailed_description>
	<criteria>The inclusion criterion subject follow : capable understand complying requirement study sign informed consent form ( ICF ) ; able communicate well Investigator , understand comply requirement study ; male subject age 21 50 year , inclusive ( Part A Cohorts 5 , 6 7 Part B ) ; male subject female subject non childbearing potential age â‰¥55 year ( Cohort 8 Part B ) ; body mass index ( BMI ) range 18 30 kg/m2 , inclusive ; healthy , determine pre study medical history , physical examination , vital sign measurement , electrocardiogram ( ECG ; 12 lead reporting RR , PR , QRS , correct QT [ QTc ] QT interval correct heart rate use Fridericia 's formula [ QTcF ] ) record evidence clinically relevant medical disorder base opinion Investigator ; whose outofnormal range clinical laboratory test result clinically relevant acceptable Investigator ; male subject must willing use barrier contraception sexual intercourse , i.e . condom , even partner postmenopausal , surgically sterile use accepted contraceptive method , first day dose administration 3 month last dose administration ; The exclusion criterion subject follow : participate study involve another investigational device drug study within 90 day prior randomisation study ; history drug hypersensitivity reaction hypersensitivity drug chemically related IP ; history evidence clinically significant disorder , condition disease ( include , limited , cardiopulmonary , oncologic , autoimmune , immunogenic , renal , metabolic , haematological psychiatric ) , , opinion Investigator , would pose risk subject safety interfere study evaluation , procedures completion ; existence surgical medical condition , judgement Investigator , may interfere absorption , distribution , metabolism excretion IP ; clinically significant history evidence active suspect bacterial , viral , fungal parasitic infection within 30 day prior randomisation ( e.g . common cold , viral syndrome , flulike symptom , etc . ) ; active recent history ( within 30 day prior randomisation ) acute viral infection skin ( e.g . Herpes simplex , Molluscum contagiosum ) ; active history psoriasis , firstdegree relative active history psoriasis ; know history evidence active latent tuberculosis infection ( e.g . positive tuberculin skin test show induration &gt; 5 mm positive tuberculin blood test ) absence previous Bacillus Calmette Guerin vaccination , recent exposure ( within 6 month prior randomisation study ) individual active tuberculosis intention travel country high risk tuberculosis study period ( include follow period ) ; history autoimmune disease include limited lupus , rheumatoid arthritis , autoimmune thyroid disease immune thrombocytopenia ; QT QTcF value high 450 m screen ; history regular alcohol consumption ( within 6 month prior randomisation study ) , define : average weekly intake great 21 unit average daily intake great 3 unit . One unit equivalent half pint ( 220 mL ) beer 1 ( 25 mL ) measure spirit 1 glass ( 125 mL ) wine ;</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>